- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07713823
Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical Cases
July 15, 2026 updated by: Jiang Long, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Combining retrospective observational research with artificial intelligence data engineering.
Collecting historical electronic medical record data, and through data governance and annotation by artificial medical experts, constructing a structured knowledge base.
Study Overview
Status
Not yet recruiting
Study Type
Observational
Enrollment (Estimated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Long Jiang, MD
- Phone Number: 18017317460
- Email: jiang.long@shgh.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Real pancreatic cancer diagnosis and treatment cases treated in the hospital
Description
Inclusion Criteria:
- Real inpatient cases of pancreatic cancer diagnosis and treatment;
- Prioritize the inclusion of cases with MDT discussion records, difficult and complex cases, and fatal cases;
- Possess complete electronic medical information (including but not limited to: outpatient medical records, inpatient medical records including admission records, progress notes, surgery/procedure records, nursing records, examination and test reports, doctor's orders, discharge/death records, etc.); -
Exclusion Criteria:
- Cases that only underwent a brief transition in emergency/outpatient departments and did not form a closed loop of diagnosis and treatment;
- Cases with incomplete diagnosis and treatment information and missing key indicators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Build a high-quality dedicated large model enhanced retrieval knowledge base for pancreatic cancer with a total of no less than 3,000 cases.
Time Frame: May 2028
|
Combining retrospective observational studies with AI data engineering.
Collect historical electronic medical record data and, through data management and expert medical labeling, build a structured knowledge base.
|
May 2028
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2026
Primary Completion (Estimated)
July 31, 2027
Study Completion (Estimated)
May 31, 2028
Study Registration Dates
First Submitted
July 13, 2026
First Submitted That Met QC Criteria
July 15, 2026
First Posted (Actual)
July 20, 2026
Study Record Updates
Last Update Posted (Actual)
July 20, 2026
Last Update Submitted That Met QC Criteria
July 15, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIT2026-152
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsUnited States, Japan, South Korea
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Brown UniversityThe Miriam Hospital; Rhode Island Hospital; Rakuten Medical, Inc.Not yet recruitingPancreatic Cancer Resectable | Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection | Pancreatic Cancer BorderlineUnited States
-
The First Affiliated Hospital with Nanjing Medical...Peking University Cancer Hospital & InstituteNot yet recruiting
-
Tianjin Medical University Cancer Institute and...Recruiting
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of UtahNovartis Pharmaceuticals; Huntsman Cancer InstituteTerminatedMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, AdultUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer